{"id":"colistin","rwe":[{"pmid":"41901706","year":"2026","title":"Fluoroquinolone-Resistant Avian Pathogenic Escherichia coli Isolated from Asymptomatic Broiler Chickens in a Slaughterhouse in Northern Thailand.","finding":"","journal":"Pathogens (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41900447","year":"2026","title":"First Report and Comprehensive Risk Index of bla(IMP-1)-Harboring Brucella anthropi in Municipal Wastewater-Irrigated Soil.","finding":"","journal":"Microorganisms","studyType":"Clinical Study"},{"pmid":"41894365","year":"2026","title":"A natural probioenzyme strategy as an effective alternative to antibiotics against multidrug-resistant Klebsiella pneumoniae in broilers: Benefits for growth, immunity, and organ health.","finding":"","journal":"PloS one","studyType":"Clinical Study"},{"pmid":"41892479","year":"2026","title":"Molecular Characterization of Colistin-Resistant Clinical Acinetobacter baumannii from Northern Greece: Phenotypic Colistin Susceptibility and lpx/pmrCAB Mutational Profiles.","finding":"","journal":"Antibiotics (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41892449","year":"2026","title":"Analysis of Antibiotic Consumption Trends and Pathogens' Epidemiological Profile Within a Multidisciplinary Clinical Hospital from Romania.","finding":"","journal":"Antibiotics (Basel, Switzerland)","studyType":"Clinical Study"}],"_fda":{"id":"ec1e8a16-a5be-4ff7-a8fe-e0cbfd25aea6","set_id":"9c6fc1c7-3350-42ae-b999-aca48e704bb1","openfda":{"unii":["WP15DXU577","3X7931PO74","057Y626693","JI2B19CR0R"],"route":["AURICULAR (OTIC)"],"rxcui":["854992","854997"],"spl_id":["ec1e8a16-a5be-4ff7-a8fe-e0cbfd25aea6"],"brand_name":["Cortisporin TC"],"spl_set_id":["9c6fc1c7-3350-42ae-b999-aca48e704bb1"],"package_ndc":["63481-529-10"],"product_ndc":["63481-529"],"generic_name":["COLISTIN SULFATE, NEOMYCIN SULFATE, THONZONIUM BROMIDE AND HYDROCORTISONE ACETATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["COLISTIN SULFATE","HYDROCORTISONE ACETATE","NEOMYCIN SULFATE","THONZONIUM BROMIDE"],"manufacturer_name":["Endo USA, Inc."],"application_number":["NDA050356"],"is_original_packager":[true]},"version":"6","warnings":["WARNINGS Neomycin can induce permanent sensorineural hearing loss due to cochlear damage, mainly destruction of hair cells in the organ of Corti. The risk is greater with prolonged use. Therapy should be limited to 10 consecutive days (See PRECAUTIONS-General ). Patients being treated with eardrops containing neomycin should be under close clinical observation. Cortisporin ® TC Otic should be used cautiously in any patient with a perforated tympanic membrane. Neomycin sulfate may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical neomycin is not known. Discontinue promptly if sensitivity or irritation occurs. When using neomycin-containing products to control secondary infection in the chronic dermatoses, such as chronic otitis externa or stasis dermatitis, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin. The manifestation of sensitization to neomycin is usually a low-grade reddening with swelling, dry scaling, and itching; it may be manifest simply as a failure to heal. Periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. These symptoms regress quickly on withdrawing the medication. Neomycin containing applications should be avoided for the patient thereafter."],"pregnancy":["Pregnancy Teratogenic Effects Pregnancy Category C There are no adequate and well controlled studies of Cortisporin ® TC Otic in pregnant women. It is not known whether Cortisporin ® TC Otic can cause fetal harm when administered to a pregnant woman. Colistimethate sodium, the methanesulfonate salt of colistin, was not teratogenic in rats or rabbits given intramuscular doses up to 20 mg/kg (equivalent to 9.3 mg/kg of colisitin base, approximately 30 times (rats) or 55 times (rabbits) the clinical daily dose based on body surface area and assuming 100% absorption from the ear). Increased resorptions were observed in rabbits at 20 mg/kg, but not 10 mg/kg (equivalent to 4.15 mg/kg of colistin base). Decreased pup survival at weaning was observed in rats at 20 mg/kg, a maternally toxic dose of colistin, but not 10 mg/kg. Colistin has not been shown to have any adverse effects on the developing embryo or fetus at doses relevant to the amount that will be delivered ototopically at the recommended clinical doses. Although aminoglycosides can cause congenital deafness in humans if administered during pregnancy, significant systemic levels of neomycin would not be anticipated when Cortisporin ® TC Otic is used as directed. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Cortisporin ® TC Otic should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."],"description":["DESCRIPTION Cortisporin ® TC Otic with Neomycin and Hydrocortisone (colistin sulfate—neomycin sulfate—thonzonium bromide—hydrocortisone acetate otic suspension) is a sterile antibacterial and anti-inflammatory aqueous suspension containing in each mL: Colistin base activity, 3 mg (as the sulfate); Neomycin base activity, 3.3 mg (as the sulfate); Hydrocortisone acetate, 10 mg (1%); Thonzonium bromide, 0.5 mg (0.05%); Polysorbate 80, acetic acid, and sodium acetate in a buffered aqueous vehicle. Thimerosal (mercury derivative), 0.002%, is added as a preservative. It is a nonviscous liquid, buffered at pH 5, for instillation into the canal of the external ear or direct application to the affected aural skin. The structural formulas of colistin sulfate (mixture of Colistin A & B), neomycin sulfate (mixture of neomycin A, B & C), hydrocortisone acetate ((11β)-21-(acetyloxy)-11,17-dihydroxypregn) methyl]-2 pyrimidinylamino] ethyl]-N,N-dimethyl-1-hexadecanaminium, bromide) are represented below: Thonzonium Bromide Colistin sulfate Neomycin A Neomycin B Sulfate Hydrocortisone Acetate Neomycin C Sulfate Thonzonium Bromide Colistin Sulfate Neomycin A Neomycin B Sulfate Hydrocortisone Acetate Neomycin C Sulfate"],"precautions":["PRECAUTIONS General As with any other antibiotic preparation, prolonged treatment may result in overgrowth of nonsusceptible organisms and fungi. If the infection is not improved after one week, cultures should be repeated to verify the identity of the organism and to determine whether therapy should be changed. Treatment should not be continued for longer than ten days. Allergic cross-reactions may occur which could prevent the use of any or all of the aminoglycoside antibiotics for the treatment of future infections. Information for Patients Avoid contaminating the dropper with material from the ear, fingers, or other source. This caution is necessary if the sterility of the drops is to be preserved. If sensitization or irritation occurs, discontinue use immediately and contact your physician. Do not use in the eyes. If you prefer to warm the medication before using it, do not heat the suspension above body temperature in order to avoid loss of potency. SHAKE WELL BEFORE USING. Laboratory Tests Systemic effects of excessive levels of hydrocortisone may include a reduction in the number of circulating eosinophils and a decrease in urinary excretion of 17-hydroxycorticosteroids. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal carcinogenicity studies have not been performed with colistin or neomycin, or Cortisporin ® TC Otic. An increased incidence of chromosome aberrations in human lymphocytes has been reported following in vitro exposure to colistin or neomycin. Fertility studies have not been performed with neomycin, but reports from the scientific literature suggest that it may decrease spermatogenesis in rats. No adverse effects on fertility were observed in male or female rats given intramuscular doses of colistimethate sodium, the methanesulfonate salt of colistin, up to 20 mg/kg (equivalent to 9.3 mg/kg of colistin base). This is approximately 30 times the clinical daily dose based on body surface area, assuming 100% absorption from the ear; however, significant systemic levels of colistin or neomycin would not be anticipated in humans when Cortisporin ® TC Otic is used as directed. Long term studies in rodents showed no evidence of carcinogenicity attributable to oral administration of corticosteroids. Mutagenicity studies with hydrocortisone were negative. Studies have not been performed to evaluate the effect on fertility of topical corticosteroids. Pregnancy Teratogenic Effects Pregnancy Category C There are no adequate and well controlled studies of Cortisporin ® TC Otic in pregnant women. It is not known whether Cortisporin ® TC Otic can cause fetal harm when administered to a pregnant woman. Colistimethate sodium, the methanesulfonate salt of colistin, was not teratogenic in rats or rabbits given intramuscular doses up to 20 mg/kg (equivalent to 9.3 mg/kg of colisitin base, approximately 30 times (rats) or 55 times (rabbits) the clinical daily dose based on body surface area and assuming 100% absorption from the ear). Increased resorptions were observed in rabbits at 20 mg/kg, but not 10 mg/kg (equivalent to 4.15 mg/kg of colistin base). Decreased pup survival at weaning was observed in rats at 20 mg/kg, a maternally toxic dose of colistin, but not 10 mg/kg. Colistin has not been shown to have any adverse effects on the developing embryo or fetus at doses relevant to the amount that will be delivered ototopically at the recommended clinical doses. Although aminoglycosides can cause congenital deafness in humans if administered during pregnancy, significant systemic levels of neomycin would not be anticipated when Cortisporin ® TC Otic is used as directed. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Cortisporin ® TC Otic should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers Hydrocortisone and colistin sulfate appear in human milk following oral administration of the drugs. Since systemic absorption of these drugs may occur when they are used topically, caution should be exercised when Cortisporin ® TC Otic Suspension is used by a nursing woman. Pediatric Use See DOSAGE AND ADMINISTRATION . The safety and effectiveness of Cortisporin ® TC Otic in infants below one year of age have not been established. The efficacy of Cortisporin ® TC Otic in pediatric patients one year or older in the treatment of superficial bacterial infections of the external auditory canal and for the treatment of infections of mastoidectomy and fenestration cavities has been demonstrated in a controlled clinical trial. Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients."],"how_supplied":["HOW SUPPLIED Cortisporin ® TC Otic is supplied as: NDC 63481-529-10 10 mL bottle with dropper Each mL contains: Colistin sulfate equivalent to 3 mg of colistin base activity, Neomycin sulfate equivalent to 3.3 mg neomycin base activity, Hydrocortisone acetate 10 mg (1%), Thonzonium bromide 0.5 mg (0.05%), and Polysorbate 80 in an aqueous vehicle buffered with acetic acid and sodium acetate. Thimerosal (mercury derivative) 0.002% is added as a preservative. A sterilized dropper-cap assembly for use on the bottle of suspension is included in the package. Shake well before using. Store at 20° to 25°C (68° to 77°F). Rx only."],"microbiology":["Microbiology Together, colistin sulfate and neomycin sulfate have bactericidal activity against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. Aerobic gram-positive microorganisms: Staphylococcus aureus. Aerobic gram-negative microorganisms: Enterobacter aerogenes Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa. Susceptibility Tests: It is not recommended that colistin sulfate or neomycin sulfate be routinely tested and reported by clinical microbiology laboratories."],"geriatric_use":["Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients."],"pediatric_use":["Pediatric Use See DOSAGE AND ADMINISTRATION . The safety and effectiveness of Cortisporin ® TC Otic in infants below one year of age have not been established. The efficacy of Cortisporin ® TC Otic in pediatric patients one year or older in the treatment of superficial bacterial infections of the external auditory canal and for the treatment of infections of mastoidectomy and fenestration cavities has been demonstrated in a controlled clinical trial."],"effective_time":"20240801","nursing_mothers":["Nursing Mothers Hydrocortisone and colistin sulfate appear in human milk following oral administration of the drugs. Since systemic absorption of these drugs may occur when they are used topically, caution should be exercised when Cortisporin ® TC Otic Suspension is used by a nursing woman."],"laboratory_tests":["Laboratory Tests Systemic effects of excessive levels of hydrocortisone may include a reduction in the number of circulating eosinophils and a decrease in urinary excretion of 17-hydroxycorticosteroids."],"adverse_reactions":["ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity (see WARNINGS section) and nephrotoxicity have also been reported. Adverse reactions have occurred with topical use of antibiotic combinations. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population. In another study the incidence was found to be approximately 1%. The following local adverse events have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. For medical advice about adverse reactions contact your medical professional. To report SUSPECTED ADVERSE REACTIONS, contact Endo at 1-800-462-3636 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["CONTRAINDICATIONS This product is contraindicated in those individuals who have shown hypersensitivity to any of its components. This product should not be used if the external auditory canal disorder is suspected or known to be due to cutaneous viral infection (e.g., herpes simplex virus or varicella zoster virus)."],"general_precautions":["General As with any other antibiotic preparation, prolonged treatment may result in overgrowth of nonsusceptible organisms and fungi. If the infection is not improved after one week, cultures should be repeated to verify the identity of the organism and to determine whether therapy should be changed. Treatment should not be continued for longer than ten days. Allergic cross-reactions may occur which could prevent the use of any or all of the aminoglycoside antibiotics for the treatment of future infections."],"teratogenic_effects":["Teratogenic Effects Pregnancy Category C There are no adequate and well controlled studies of Cortisporin ® TC Otic in pregnant women. It is not known whether Cortisporin ® TC Otic can cause fetal harm when administered to a pregnant woman. Colistimethate sodium, the methanesulfonate salt of colistin, was not teratogenic in rats or rabbits given intramuscular doses up to 20 mg/kg (equivalent to 9.3 mg/kg of colisitin base, approximately 30 times (rats) or 55 times (rabbits) the clinical daily dose based on body surface area and assuming 100% absorption from the ear). Increased resorptions were observed in rabbits at 20 mg/kg, but not 10 mg/kg (equivalent to 4.15 mg/kg of colistin base). Decreased pup survival at weaning was observed in rats at 20 mg/kg, a maternally toxic dose of colistin, but not 10 mg/kg. Colistin has not been shown to have any adverse effects on the developing embryo or fetus at doses relevant to the amount that will be delivered ototopically at the recommended clinical doses. Although aminoglycosides can cause congenital deafness in humans if administered during pregnancy, significant systemic levels of neomycin would not be anticipated when Cortisporin ® TC Otic is used as directed. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Cortisporin ® TC Otic should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."],"storage_and_handling":["Store at 20° to 25°C (68° to 77°F). Rx only."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Neomycin sulfate is an aminoglycoside antibiotic which inhibits protein synthesis, disrupting the normal cycle of ribosomal function. Hydrocortisone acetate is a corticosteroid hormone which is thought to act by regulating the rate of protein synthesis; it controls inflammation, edema, pruritus and other dermal reactions. Corticosteroids suppress the inflammatory response to a variety of agents and they may delay healing. Since corticoids may inhibit the body's defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case. The relative potency of corticosteroids depends on the molecular structure, concentration, and release from the vehicle. Thonzonium bromide is a surface-active agent that promotes tissue contact by dispersion and penetration of the cellular debris and exudate. Microbiology Together, colistin sulfate and neomycin sulfate have bactericidal activity against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. Aerobic gram-positive microorganisms: Staphylococcus aureus. Aerobic gram-negative microorganisms: Enterobacter aerogenes Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa. Susceptibility Tests: It is not recommended that colistin sulfate or neomycin sulfate be routinely tested and reported by clinical microbiology laboratories."],"indications_and_usage":["INDICATIONS AND USAGE Cortisporin ® TC Otic is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics."],"information_for_patients":["Information for Patients Avoid contaminating the dropper with material from the ear, fingers, or other source. This caution is necessary if the sterility of the drops is to be preserved. If sensitization or irritation occurs, discontinue use immediately and contact your physician. Do not use in the eyes. If you prefer to warm the medication before using it, do not heat the suspension above body temperature in order to avoid loss of potency. SHAKE WELL BEFORE USING."],"spl_unclassified_section":["Manufactured for: Endo USA Malvern, PA 19355 © 2024 Endo, Inc. or one of its affiliates. Revised: 07/2024"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Therapy with this product should be limited to 10 days (See WARNINGS ). The external auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator. When using the calibrated dropper: For adults, 5 drops of the suspension should be instilled into the affected ear 3 or 4 times daily. For pediatric patients, 4 drops are suggested because of the smaller capacity of the ear canal. The patient should lie with the affected ear upward and then the drops should be instilled. This position should be maintained for 5 minutes to facilitate penetration of the drops into the ear canal. Repeat, if necessary, for the opposite ear. If preferred, a cotton wick may be inserted into the canal and then the cotton may be saturated with the suspension. This wick should be kept moist by adding further solution every 4 hours. The wick should be replaced at least once every 24 hours."],"spl_product_data_elements":["Cortisporin TC colistin sulfate, neomycin sulfate, thonzonium bromide and hydrocortisone acetate COLISTIN SULFATE COLISTIN NEOMYCIN SULFATE NEOMYCIN THONZONIUM BROMIDE THONZONIUM HYDROCORTISONE ACETATE HYDROCORTISONE ACETIC ACID SODIUM ACETATE THIMEROSAL POLYSORBATE 80"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 10 mL Bottle Carton 10_mL_Bottle_Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal carcinogenicity studies have not been performed with colistin or neomycin, or Cortisporin ® TC Otic. An increased incidence of chromosome aberrations in human lymphocytes has been reported following in vitro exposure to colistin or neomycin. Fertility studies have not been performed with neomycin, but reports from the scientific literature suggest that it may decrease spermatogenesis in rats. No adverse effects on fertility were observed in male or female rats given intramuscular doses of colistimethate sodium, the methanesulfonate salt of colistin, up to 20 mg/kg (equivalent to 9.3 mg/kg of colistin base). This is approximately 30 times the clinical daily dose based on body surface area, assuming 100% absorption from the ear; however, significant systemic levels of colistin or neomycin would not be anticipated in humans when Cortisporin ® TC Otic is used as directed. Long term studies in rodents showed no evidence of carcinogenicity attributable to oral administration of corticosteroids. Mutagenicity studies with hydrocortisone were negative. Studies have not been performed to evaluate the effect on fertility of topical corticosteroids."]},"tags":[{"label":"colistin","category":"class"},{"label":"Peptide","category":"modality"},{"label":"Melanocortin receptor 3","category":"target"},{"label":"MC3R","category":"gene"},{"label":"MC5R","category":"gene"},{"label":"MC4R","category":"gene"},{"label":"A07AA10","category":"atc"},{"label":"Auricular (Otic)","category":"route"},{"label":"Suspension","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Enterobacter Infection","category":"indication"},{"label":"Infection due to Escherichia coli","category":"indication"},{"label":"Klebsiella Infections","category":"indication"},{"label":"Mastoidectomy Cavity Infections","category":"indication"},{"label":"Otitis externa","category":"indication"},{"label":"Pseudomonas Aeruginosa Infections","category":"indication"},{"label":"Par Sterile Products","category":"company"},{"label":"Approved 1960s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"CENTRAL NERVOUS SYSTEM LYMPHOMA","source":"FDA FAERS","actionTaken":"1 reports"}],"commonSideEffects":[{"effect":"Skin atrophy","drugRate":"reported","severity":"unknown"},{"effect":"Secondary infection","drugRate":"reported","severity":"unknown"},{"effect":"Maceration of the skin","drugRate":"reported","severity":"unknown"},{"effect":"Miliaria","drugRate":"reported","severity":"unknown"},{"effect":"Hypertrichosis","drugRate":"reported","severity":"unknown"},{"effect":"Hypopigmentation","drugRate":"reported","severity":"unknown"},{"effect":"Folliculitis","drugRate":"reported","severity":"unknown"},{"effect":"Dryness","drugRate":"reported","severity":"unknown"},{"effect":"Irritation","drugRate":"reported","severity":"unknown"},{"effect":"Itching","drugRate":"reported","severity":"unknown"},{"effect":"Burning","drugRate":"reported","severity":"unknown"},{"effect":"Acneiform eruptions","drugRate":"reported","severity":"unknown"},{"effect":"Allergic contact dermatitis","drugRate":"reported","severity":"unknown"},{"effect":"Perioral dermatitis","drugRate":"reported","severity":"unknown"},{"effect":"Nephrotoxicity","drugRate":"reported","severity":"unknown"},{"effect":"Ototoxicity","drugRate":"reported","severity":"unknown"},{"effect":"Allergic sensitization","drugRate":"1%","severity":"common","_validated":true},{"effect":"Neomycin-induced allergic skin reactions","drugRate":"0.09%","severity":"mild","_validated":true}],"contraindications":["Bullous myringitis","Fungal ear infection","Herpes simplex","Herpes zoster auricularis","Kidney disease","Myasthenia gravis","Neuromuscular block, function","Perforation of tympanic membrane","Pseudomembranous enterocolitis","Tuberculosis of ear","Viral ear infection"],"specialPopulations":{"Pregnancy":"There are no adequate and well controlled studies of Cortisporin(R)-TC Otic Suspension in pregnant women. It is not known whether Cortisporin(R)-TC Otic Suspension can cause fetal harm when administered to pregnant woman. Colistimethate sodium, the methanesulfonate salt of colistin, was not teratogenic in rats or rabbits given intramuscular doses up to 20 mg/kg (equivalent to 9.3 mg/kg of colisitin base, approximately 30 times (rats) or 55 ti","Geriatric use":"No overall differences in safety or effectiveness have been observed between elderly and younger patients.","Paediatric use":"The safety and effectiveness of Cortisporin(R)-TC Otic Suspension in infants below one year of age have not been established. The efficacy of Cortisporin(R)-TC Otic Suspension in pediatric patients one year or older in the treatment of superficial bacterial infections of the external auditory canal and for the treatment of infections of mastoidectomy and fenestration cavities has been demonstrated in controlled clinical trial."}},"trials":[],"aliases":[],"company":"Par Sterile Products","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=COLISTIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:54:46.311898+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:54:52.756709+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:54:44.951751+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=COLISTIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:54:53.577672+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:54:43.205265+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:54:43.205340+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:54:55.104049+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6067481/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:54:54.064309+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA050356","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:54:43.205351+00:00"}},"allNames":"coly-mycin s","offLabel":[],"synonyms":["colistin","colimycin","Polymyxin E","colistin sulfate","colistins sulfate"],"timeline":[{"date":"1962-05-17","type":"positive","source":"DrugCentral","milestone":"FDA approval (Par Sterile Products)"}],"approvals":[{"date":"1962-05-17","orphan":false,"company":"PAR STERILE PRODUCTS","regulator":"FDA"}],"brandName":"Coly-Mycin S","ecosystem":[{"indication":"Enterobacter Infection","otherDrugs":[{"name":"colistimethate sodium","slug":"colistimethate-sodium","company":"Par Sterile Products"}],"globalPrevalence":null},{"indication":"Infection due to Escherichia coli","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"aztreonam","slug":"aztreonam","company":"Bristol Myers Squibb"}],"globalPrevalence":null},{"indication":"Klebsiella Infections","otherDrugs":[{"name":"colistimethate sodium","slug":"colistimethate-sodium","company":"Par Sterile Products"}],"globalPrevalence":null},{"indication":"Mastoidectomy Cavity Infections","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"hydrocortisone","slug":"hydrocortisone","company":"Merck"},{"name":"neomycin","slug":"neomycin","company":"Monarch Pharms"}],"globalPrevalence":null},{"indication":"Otitis externa","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"acetic acid","slug":"acetic-acid","company":"Hi Tech Pharma"},{"name":"benzalkonium","slug":"benzalkonium","company":""},{"name":"chloramphenicol","slug":"chloramphenicol","company":"Parkedale"}],"globalPrevalence":null},{"indication":"Pseudomonas Aeruginosa Infections","otherDrugs":[{"name":"colistimethate sodium","slug":"colistimethate-sodium","company":"Par Sterile Products"}],"globalPrevalence":null}],"mechanism":{"target":"Melanocortin receptor 3","novelty":"Follow-on","targets":[{"gene":"MC3R","source":"DrugCentral","target":"Melanocortin receptor 3","protein":"Melanocortin receptor 3"},{"gene":"MC5R","source":"DrugCentral","target":"Melanocortin receptor 5","protein":"Melanocortin receptor 5"},{"gene":"MC4R","source":"DrugCentral","target":"Melanocortin receptor 4","protein":"Melanocortin receptor 4"},{"gene":"FYN","source":"DrugCentral","target":"Tyrosine-protein kinase Fyn","protein":"Tyrosine-protein kinase Fyn"},{"gene":"EGFR","source":"DrugCentral","target":"Epidermal growth factor receptor","protein":"Epidermal growth factor receptor"},{"gene":"ERBB2","source":"DrugCentral","target":"Receptor tyrosine-protein kinase erbB-2","protein":"Receptor tyrosine-protein kinase erbB-2"}],"modality":"Small Molecule","drugClass":"colistin","explanation":"","oneSentence":"","technicalDetail":"Coly-Mycin S, a polymyxin antibiotic, exerts its bactericidal effect by interacting with the bacterial cell membrane, increasing its permeability and disrupting the function of the lipopolysaccharide layer, ultimately leading to cell lysis and death."},"commercial":{"launchDate":"1962","_launchSource":"DrugCentral (FDA 1962-05-17, PAR STERILE PRODUCTS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4425","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=COLISTIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=COLISTIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:17:20.539306","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:54:58.437578+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"neomycin","drugSlug":"neomycin","fdaApproval":"1957-03-26","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nystatin","drugSlug":"nystatin","fdaApproval":"1964-07-08","genericCount":48,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"natamycin","drugSlug":"natamycin","fdaApproval":"1978-10-30","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"streptomycin","drugSlug":"streptomycin","fdaApproval":"1946-02-18","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"Polymyxin B","drugSlug":"polymyxin-b","fdaApproval":"1957-03-26","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"paromomycin","drugSlug":"paromomycin","fdaApproval":"1969-03-24","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"amphotericin B","drugSlug":"amphotericin-b","fdaApproval":"1964-11-12","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"kanamycin","drugSlug":"kanamycin","fdaApproval":"1973-02-13","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"vancomycin","drugSlug":"vancomycin","fdaApproval":"1964-11-06","patentExpiry":"Nov 6, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"rifaximin","drugSlug":"rifaximin","fdaApproval":"2004-05-25","patentExpiry":"Sep 2, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"fidaxomicin","drugSlug":"fidaxomicin","fdaApproval":"2011-05-27","patentExpiry":"Sep 4, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"rifamycin","drugSlug":"rifamycin","fdaApproval":"2018-11-16","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"colistin","indications":{"approved":[{"name":"Enterobacter Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Infection due to Escherichia coli","source":"DrugCentral","snomedId":71057007,"regulator":"FDA"},{"name":"Klebsiella Infections","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Mastoidectomy Cavity Infections","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Otitis externa","source":"DrugCentral","snomedId":3135009,"regulator":"FDA"},{"name":"Pseudomonas Aeruginosa Infections","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[{"name":"Chronic purulent otitis media","source":"DrugCentral","drugName":"COLISTIN","evidenceCount":11,"evidenceLevel":"moderate"},{"name":"Pseudomonas Respiratory Tract Infection in Cystic Fibrosis","source":"DrugCentral","drugName":"COLISTIN","evidenceCount":85,"evidenceLevel":"strong"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"neomycin","brandName":"neomycin","genericName":"neomycin","approvalYear":"1957","relationship":"same-class"},{"drugId":"nystatin","brandName":"nystatin","genericName":"nystatin","approvalYear":"1964","relationship":"same-class"},{"drugId":"natamycin","brandName":"natamycin","genericName":"natamycin","approvalYear":"1978","relationship":"same-class"},{"drugId":"streptomycin","brandName":"streptomycin","genericName":"streptomycin","approvalYear":"1946","relationship":"same-class"},{"drugId":"polymyxin-b","brandName":"Polymyxin B","genericName":"Polymyxin B","approvalYear":"1957","relationship":"same-class"},{"drugId":"paromomycin","brandName":"paromomycin","genericName":"paromomycin","approvalYear":"1969","relationship":"same-class"},{"drugId":"amphotericin-b","brandName":"amphotericin B","genericName":"amphotericin B","approvalYear":"1964","relationship":"same-class"},{"drugId":"kanamycin","brandName":"kanamycin","genericName":"kanamycin","approvalYear":"1973","relationship":"same-class"},{"drugId":"vancomycin","brandName":"vancomycin","genericName":"vancomycin","approvalYear":"1964","relationship":"same-class"},{"drugId":"rifaximin","brandName":"rifaximin","genericName":"rifaximin","approvalYear":"2004","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07487116","phase":"","title":"Phenotypic and Genotypic Detection of Colistin Resistance","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-08","conditions":["Patients With Multi Drug Resistant Gram-negative Bacteria","Colistin Resistance in Bacteria"],"enrollment":90,"completionDate":"2029-08"},{"nctId":"NCT06087536","phase":"PHASE2","title":"A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex","status":"RECRUITING","sponsor":"Omnix Medical Ltd","startDate":"2026-03","conditions":["Hospital-acquired Bacterial Pneumonia","Ventilator-associated Bacterial Pneumonia"],"enrollment":54,"completionDate":"2027-03"},{"nctId":"NCT06966284","phase":"","title":"A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection","status":"RECRUITING","sponsor":"TTY Biopharm","startDate":"2025-11-26","conditions":["Bacteremia Caused by Gram-Negative Bacteria","Bacterial Pneumonia"],"enrollment":480,"completionDate":"2028-11-30"},{"nctId":"NCT06230614","phase":"NA","title":"Effect of Diluent Volume on Colistin Inhalation Therapy","status":"RECRUITING","sponsor":"Fu Jen Catholic University","startDate":"2024-03-10","conditions":["Inhalation Pneumonia"],"enrollment":60,"completionDate":"2026-07-31"},{"nctId":"NCT06488794","phase":"PHASE2,PHASE3","title":"Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Fattouma Bourguiba","startDate":"2027-01-01","conditions":["Ventilator Associated Pneumonia"],"enrollment":400,"completionDate":"2028-12-31"},{"nctId":"NCT06650384","phase":"PHASE2,PHASE3","title":"Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid in Colistin-Induced Nephrotoxicity","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-11-01","conditions":["Nephrotoxicity"],"enrollment":180,"completionDate":"2026-02-01"},{"nctId":"NCT06440304","phase":"PHASE4","title":"Therapeutic Options for CRAB","status":"RECRUITING","sponsor":"Clinical Hospital Centre Zagreb","startDate":"2025-01-30","conditions":["Infections, Bacterial","Sepsis Bacterial"],"enrollment":108,"completionDate":"2027-02"},{"nctId":"NCT07326540","phase":"PHASE3","title":"Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","status":"NOT_YET_RECRUITING","sponsor":"BioVersys SAS","startDate":"2026-03-20","conditions":["Hospital Acquired Bacterial Pneumonia (HABP)","Ventilator Associated Bacterial Pneumonia (VABP)","Colistin Resistanrt ABC","Acinetobacter Baumannii-calcoaceticus Complex"],"enrollment":248,"completionDate":"2028-03-30"},{"nctId":"NCT03477292","phase":"NA","title":"7-days Versus 14 Days of Antibiotics Therapy for Ventilator Associated Pneumonia","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2018-03-01","conditions":["Ventilator Associated Pneumonia"],"enrollment":41,"completionDate":"2024-12-31"},{"nctId":"NCT07172932","phase":"","title":"ANTIBIOTIC-RESISTANT ENTEROBACTERALES BLOODSTREAM INFECTIONS AND RISK FACTORS IN PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT","status":"COMPLETED","sponsor":"Ankara City Hospital Bilkent","startDate":"2019-09-01","conditions":["Bloodstream Infections","Enterobacteriaceae Infections","Intensive Care (ICU)","Antibiotic Resistant Infection"],"enrollment":314,"completionDate":"2023-01-30"},{"nctId":"NCT06472271","phase":"","title":"Colistin Dosage Prsonalization Approach","status":"RECRUITING","sponsor":"Mahmoud I Mostafa","startDate":"2024-07-30","conditions":["Colistin Adverse Reaction"],"enrollment":100,"completionDate":"2025-10-30"},{"nctId":"NCT05922124","phase":"PHASE4","title":"Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2024-09-01","conditions":["Carbapenem Resistant Bacterial Infection","Acinetobacter Bacteremia","Acinetobacter Pneumonia"],"enrollment":734,"completionDate":"2026-09"},{"nctId":"NCT07089186","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-04-12","conditions":["Hospital-acquired Bacterial Pneumonia (HABP)","Ventilator-associated Bacterial Pneumonia (VABP)","Complicated Intra-abdominal Infection (cIAI)","Complicated Urinary Tract Infection (cUTI)","Bloodstream Infection (BSI)"],"enrollment":80,"completionDate":"2027-04"},{"nctId":"NCT07082465","phase":"","title":"Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four Hospitals in Thailand","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2025-08-01","conditions":["Drug Resistance","Bacterial","Bacteremia"],"enrollment":108000,"completionDate":"2026-08-16"},{"nctId":"NCT06834971","phase":"NA","title":"Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-07-15","conditions":["Ventilator-Associated Pneumonia (VAP)"],"enrollment":508,"completionDate":"2026-12"},{"nctId":"NCT06843668","phase":"PHASE2,PHASE3","title":"Different Dosing Strategies of Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2023-12-25","conditions":["Critical Ill Patients","Multi Drug Resistant"],"enrollment":120,"completionDate":"2025-10-25"},{"nctId":"NCT07004049","phase":"PHASE4","title":"Optimising TREATment for Severe Gram-Negative Bacterial Infections","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-04-21","conditions":["Bloodstream Infection","Ventilator Associated Bacterial Pneumonia","Hospital Acquired Bacterial Pneumonia","Carbapenem Resistant Bacterial Infection","Multidrug Resistance"],"enrollment":600,"completionDate":"2028-12-31"},{"nctId":"NCT06051513","phase":"NA","title":"Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection","status":"RECRUITING","sponsor":"Southeast University, China","startDate":"2023-11-27","conditions":["Carbapenem-Resistant Enterobacteriaceae Infection"],"enrollment":404,"completionDate":"2025-12-31"},{"nctId":"NCT06893835","phase":"PHASE4","title":"Comparative Study of Clinical Outcomes and Safety Between Colistin and Tigecycline","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beni-Suef University","startDate":"2024-12-01","conditions":["Infection in ICU"],"enrollment":132,"completionDate":"2025-06-30"},{"nctId":"NCT05865743","phase":"PHASE3","title":"Perioperative SDD to Prevent Infectious Complications After Esophagectomy","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2024-10-21","conditions":["Esophageal Cancer"],"enrollment":854,"completionDate":"2028-06-30"},{"nctId":"NCT04764500","phase":"","title":"Developing Microbials to Fight Extended-spectrum Beta-lactamase (ESBL)-Producing Escherichia Coli","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2019-06-13","conditions":["Extended Spectrum Beta Lactamases (ESBL) E. Coli"],"enrollment":39,"completionDate":"2025-12"},{"nctId":"NCT06827756","phase":"PHASE4","title":"Comparative Study of Secondary Prophylaxis for SBP","status":"COMPLETED","sponsor":"Tanta University","startDate":"2021-03-01","conditions":["Spontaneous Bacterial Peritonitis","Cirrhoses, Liver","Ascites"],"enrollment":90,"completionDate":"2022-02-01"},{"nctId":"NCT06819462","phase":"NA","title":"Inhaled Polymyxin E to Prevent VAP","status":"NOT_YET_RECRUITING","sponsor":"Southeast University, China","startDate":"2025-02-01","conditions":["Ventilator-Associated Pneumonia (VAP)","Inha'le'd"],"enrollment":434,"completionDate":"2028-06-30"},{"nctId":"NCT05685615","phase":"PHASE2","title":"PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB","status":"COMPLETED","sponsor":"BioVersys AG","startDate":"2023-04-20","conditions":["Ventilator Associated Pneumonia"],"enrollment":39,"completionDate":"2024-12-11"},{"nctId":"NCT03329092","phase":"PHASE3","title":"A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-04-05","conditions":["Complicated Intra-abdominal Infection","Hosptial Acquired Pneumonia","Ventilator Associated Pneumonia"],"enrollment":422,"completionDate":"2023-02-23"},{"nctId":"NCT06419296","phase":"","title":"Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.","status":"COMPLETED","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2024-06-01","conditions":["Bacteremia"],"enrollment":265,"completionDate":"2024-11-19"},{"nctId":"NCT04882085","phase":"PHASE4","title":"Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-26","conditions":["Urinary Tract Infection","Acute Pyelonephritis","Hospital Acquired Pneumonia","Ventilator-associated Pneumonia","Bacteremia","Intra-abdominal Infection"],"enrollment":60,"completionDate":"2023-08-31"},{"nctId":"NCT06570850","phase":"PHASE4","title":"Colistin Monotherapy vs Colsitin-fosfomycine in CRAB Infection","status":"RECRUITING","sponsor":"Chiang Mai University","startDate":"2023-04-01","conditions":["Infection Due to Carbapenem Resistant Acinetobacter"],"enrollment":188,"completionDate":"2025-07"},{"nctId":"NCT05258851","phase":"PHASE3","title":"Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections","status":"TERMINATED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2022-06-01","conditions":["Carbapenem-Resistant Enterobacteriaceae Infection"],"enrollment":29,"completionDate":"2024-01-28"},{"nctId":"NCT05542446","phase":"PHASE4","title":"Pharmacokinetics of Colistin in Critically Ill Patients With Extracorporeal Membrane Oxygenation","status":"TERMINATED","sponsor":"St. Anne's University Hospital Brno, Czech Republic","startDate":"2022-09-01","conditions":["Colistin"],"enrollment":8,"completionDate":"2024-01-19"},{"nctId":"NCT06198764","phase":"PHASE3","title":"A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-07-06","conditions":["Mental Health Issue"],"enrollment":80,"completionDate":"2026-03"},{"nctId":"NCT03460704","phase":"PHASE3","title":"Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.","status":"TERMINATED","sponsor":"Zambon SpA","startDate":"2018-01-29","conditions":["Non Cystic Fibrosis Bronchiectasis"],"enrollment":287,"completionDate":"2022-03-15"},{"nctId":"NCT03093974","phase":"PHASE3","title":"Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2017-06-06","conditions":["Non Cystic Fibrosis Bronchiectasis"],"enrollment":377,"completionDate":"2021-04-09"},{"nctId":"NCT05613361","phase":"PHASE3","title":"The Effect of Curcumin Against Colistin-induced Nephrotoxicity","status":"UNKNOWN","sponsor":"October 6 University","startDate":"2023-01-01","conditions":["Acute Kidney Injury","Drug-Induced Nephropathy"],"enrollment":214,"completionDate":"2024-10-30"},{"nctId":"NCT02389036","phase":"PHASE3","title":"Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients","status":"COMPLETED","sponsor":"The George Institute","startDate":"2017-05-01","conditions":["Critical Illness","Sepsis","Septic Shock","Ventilator Associated Pneumonia"],"enrollment":20010,"completionDate":"2023-04-26"},{"nctId":"NCT05960084","phase":"","title":"Impact of Reducing Colistin Use on Colistin Resistance in Humans and Poultry in Indonesia","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2023-07-23","conditions":["Colonization, Asymptomatic","Colistin","Mcr-1","Antimicrobial Resistance"],"enrollment":803,"completionDate":"2025-06-01"},{"nctId":"NCT04633317","phase":"NA","title":"Aerosolized Colistin to Mechanical Ventilated Patients With Pneumonia","status":"COMPLETED","sponsor":"Chang Gung University","startDate":"2020-12-15","conditions":["Pneumonia, Bacterial"],"enrollment":60,"completionDate":"2022-07-31"},{"nctId":"NCT05862402","phase":"PHASE4","title":"Dose Optimization by Pharmacokinetic/Pharmacodynamic of Antibiotics to Improve Clinical Outcome of Carbapenem Resistant Klebsiella Pneumoniae Bloodstream Infections in Critically Ill Patients at Phramongkutklao Hospital","status":"UNKNOWN","sponsor":"Phramongkutklao College of Medicine and Hospital","startDate":"2023-05-07","conditions":["Carbapenem Resistant Klebsiella Pneumoniae"],"enrollment":76,"completionDate":"2024-06-30"},{"nctId":"NCT05850871","phase":"NA","title":"Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-01-06","conditions":["Carbapenem-Resistant Enterobacteriaceae Infection"],"enrollment":427,"completionDate":"2025-01-31"},{"nctId":"NCT05833412","phase":"","title":"Molecular Early Sepsis Identification Study","status":"UNKNOWN","sponsor":"Alejandro Rodriguez Oviedo , MD","startDate":"2023-04-12","conditions":["Sepsis","Molecular Diagnosis"],"enrollment":120,"completionDate":"2024-04-30"},{"nctId":"NCT02918409","phase":"PHASE4","title":"IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2016-08-26","conditions":["Cystic Fibrosis"],"enrollment":51,"completionDate":"2021-11-22"},{"nctId":"NCT03894046","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex","status":"COMPLETED","sponsor":"Entasis Therapeutics","startDate":"2019-09-05","conditions":["Acinetobacter Baumannii-calcoaceticus Complex","Hospital-acquired Bacterial Pneumonia","Ventilator-associated Bacterial Pneumonia","Bacteremia","Colistin Resistant ABC"],"enrollment":207,"completionDate":"2021-07-26"},{"nctId":"NCT05689229","phase":"PHASE3","title":"Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2021-08-03","conditions":["Secondary Bacterial Infection in COVID-19 Patients"],"enrollment":128,"completionDate":"2021-12-12"},{"nctId":"NCT05586815","phase":"PHASE4","title":"Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2023-01-10","conditions":["Acinetobacter Infections"],"enrollment":94,"completionDate":"2024-06-30"},{"nctId":"NCT05586438","phase":"PHASE4","title":"Pharmacokinetics of Colistin in Critically-ill Patients With AKI Who Receive SLED","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2021-10-18","conditions":["Bacterial Infections"],"enrollment":13,"completionDate":"2022-10-31"},{"nctId":"NCT01597973","phase":"PHASE3","title":"Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2012-10-06","conditions":["Pneumonia","Blood Stream Infection"],"enrollment":467,"completionDate":"2020-08-09"},{"nctId":"NCT05279586","phase":"EARLY_PHASE1","title":"Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients","status":"UNKNOWN","sponsor":"Madonna Magdy Fahmy","startDate":"2022-03","conditions":["Hepatic Encephalopathy"],"enrollment":316,"completionDate":"2023-03"},{"nctId":"NCT03971877","phase":"","title":"Detection of Colistin-resistant Isolates From Patients of Intensive Care Units and Oncohaematology Wards.","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2019-12-16","conditions":["Colistin Resistance in Bacteria"],"enrollment":1934,"completionDate":"2021-02-16"},{"nctId":"NCT04995133","phase":"PHASE4","title":"Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs.","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-14","conditions":["Hospital Infection","Multi-antibiotic Resistance","Critically Ill"],"enrollment":20,"completionDate":"2022-01-30"},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":["Osteomyelitis"],"enrollment":11,"completionDate":"2018-11-07"},{"nctId":"NCT04764058","phase":"PHASE1,PHASE2","title":"Efficacy and Safety of Colistin Based Antibiotic Therapy","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2017-09-01","conditions":["Septicemia","Bacterial Infections"],"enrollment":60,"completionDate":"2021-09-01"},{"nctId":"NCT04208763","phase":"NA","title":"A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2019-12-20","conditions":["Spontaneous Bacterial Peritonitis"],"enrollment":90,"completionDate":"2021-12-31"},{"nctId":"NCT03397914","phase":"PHASE4","title":"Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections","status":"COMPLETED","sponsor":"National Cancer Institute, Egypt","startDate":"2017-01","conditions":["Gram-Negative Bacterial Infections","Pediatric Cancer","Colistin","Colistin Adverse Reaction","MIC"],"enrollment":70,"completionDate":"2019-03"},{"nctId":"NCT01793012","phase":"","title":"Drug Monitoring of Antibiotics in Critical Care Patients","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2013-03","conditions":["ARDS","Sepsis"],"enrollment":186,"completionDate":"2015-01"},{"nctId":"NCT04489459","phase":"PHASE4","title":"Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae","status":"UNKNOWN","sponsor":"Al-Azhar University","startDate":"2019-09-21","conditions":["Treatment of Blood Stream Infections Due to Multidrug-Resistant Klebsiella Pneumoniae"],"enrollment":60,"completionDate":"2020-07"},{"nctId":"NCT03190421","phase":"NA","title":"Expanded Quantitative Urinary Culture (EQUC) vs Standard Culture (SUC) Techniques in the Clinical Care","status":"COMPLETED","sponsor":"Loyola University","startDate":"2017-06-15","conditions":["Urinary Tract Infections"],"enrollment":225,"completionDate":"2020-04-30"},{"nctId":"NCT01863719","phase":"PHASE1","title":"Aerosolized and Intravenous Colistin in Healthy Adults","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-08-06","conditions":["Pathogen Resistance","Pneumococcal Infection","Pneumonia"],"enrollment":27,"completionDate":"2017-05-04"},{"nctId":"NCT04208945","phase":"NA","title":"Nebulized Colistin for Gram Negative VAP Prevention.","status":"UNKNOWN","sponsor":"University of Thessaly","startDate":"2019-12","conditions":["Pneumonia, Ventilator-associated","Gram-Negative Pneumonia"],"enrollment":152,"completionDate":"2021-09"},{"nctId":"NCT02134106","phase":"PHASE2,PHASE3","title":"Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria","status":"WITHDRAWN","sponsor":"Tan Tock Seng Hospital","startDate":"2015-01","conditions":["Bacteremia","Healthcare-associated Pneumonia","Ventilator-associated Pneumonia"],"enrollment":0,"completionDate":"2015-12"},{"nctId":"NCT02894684","phase":"PHASE4","title":"Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis","status":"COMPLETED","sponsor":"Liverpool Heart and Chest Hospital NHS Foundation Trust","startDate":"2017-01","conditions":["Cystic Fibrosis","Infection","Pseudomonas"],"enrollment":16,"completionDate":"2019-09"},{"nctId":"NCT03409679","phase":"PHASE3","title":"Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa","status":"TERMINATED","sponsor":"Polyphor Ltd.","startDate":"2018-03-23","conditions":["Pneumonia"],"enrollment":41,"completionDate":"2019-07-17"},{"nctId":"NCT03597841","phase":"","title":"Turkish Prospective Cohort Study on Carbapenem Resistant Klebsiella Pneumonia Bacteremia","status":"COMPLETED","sponsor":"Koç University","startDate":"2018-06-25","conditions":["Klebsiella Pneumonia","Bacteremia"],"enrollment":278,"completionDate":"2019-07-22"},{"nctId":"NCT02288429","phase":"","title":"Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-09","conditions":["Colistin"],"enrollment":16,"completionDate":"2019-06"},{"nctId":"NCT01740947","phase":"PHASE4","title":"Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis?","status":"TERMINATED","sponsor":"H. Jaap Bonjer, PhD","startDate":"2013-01","conditions":["Colorectal Cancer"],"enrollment":485,"completionDate":"2017-03"},{"nctId":"NCT02452047","phase":"PHASE3","title":"Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-08-21","conditions":["Bacterial Infections"],"enrollment":50,"completionDate":"2017-09-18"},{"nctId":"NCT01970371","phase":"PHASE3","title":"A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)","status":"COMPLETED","sponsor":"Achaogen, Inc.","startDate":"2014-09-16","conditions":["Bloodstream Infections (BSI) Due to CRE","Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE","Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE","Complicated Urinary Tract Infection (cUTI) Due to CRE","Acute Pyelonephritis (AP) Due to CRE"],"enrollment":69,"completionDate":"2016-09-15"},{"nctId":"NCT02906722","phase":"PHASE3","title":"Nebulized and Intravenous Colistin in Ventilator Associated-pneumonia","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-07-31","conditions":["Ventilator-associated Pneumonia"],"enrollment":7,"completionDate":"2018-06-19"},{"nctId":"NCT03622918","phase":"NA","title":"Colistin-rifampin Combination and Colistin Monotherapy in Extensively Drug-resistant Acinetobacter Baumannii","status":"COMPLETED","sponsor":"Gangnam Severance Hospital","startDate":"2016-10-27","conditions":["Colistin","Rifampin","Acinetobacter Infections"],"enrollment":9,"completionDate":"2018-06-21"},{"nctId":"NCT03622450","phase":"PHASE2,PHASE3","title":"The Effect of Colistin Inhalation on Ventilator Associated Pneumonia","status":"COMPLETED","sponsor":"Nourhan Hassan Osama Thuraya Mohamed","startDate":"2016-01-02","conditions":["Ventilator Associated Pneumonia"],"enrollment":40,"completionDate":"2018-01-10"},{"nctId":"NCT02806141","phase":"PHASE3","title":"Aerosolized Plus Intravenous vs. Intravenous Colistin for VAP Due to Pandrugs-resistant A. Baumannii in Neonates","status":"TERMINATED","sponsor":"Hat Yai Medical Education Center","startDate":"2016-09","conditions":["Pneumonia, Ventilator-Associated","Colistin Adverse Reaction","Infection Due to Multidrug Resistant Acinetobacter","Infection Resistant to Multiple Drugs"],"enrollment":204,"completionDate":"2017-10"},{"nctId":"NCT02482961","phase":"","title":"Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection","status":"COMPLETED","sponsor":"DongGuk University","startDate":"2015-05","conditions":["Acinetobacter Infections"],"enrollment":30,"completionDate":"2018-04-04"},{"nctId":"NCT03007290","phase":"NA","title":"Clinical Usefulness of Therapeutic Drug Monitoring of Colistin in Patients Treated With Colistin.","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2016-01","conditions":["Multidrug-resistant Gram-negative Bacteria Infection"],"enrollment":15,"completionDate":"2017-12"},{"nctId":"NCT02117986","phase":"PHASE4","title":"Efficacy and Mortality of a Loading Dose of Colistin in Critical Ill Patients","status":"UNKNOWN","sponsor":"Hospital Barros Luco Trudeau","startDate":"2014-04","conditions":["Gram Negative Bacterial Infections"],"enrollment":200,"completionDate":"2018-12"},{"nctId":"NCT02966457","phase":"PHASE4","title":"A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM)","status":"COMPLETED","sponsor":"Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology","startDate":"2017-01","conditions":["Hematological Infection"],"enrollment":62,"completionDate":"2017-12"},{"nctId":"NCT02472600","phase":"PHASE2","title":"Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy","status":"UNKNOWN","sponsor":"Stephen Harbarth","startDate":"2016-02","conditions":["Intestinal Colonization With Multidrug-resistant Bacteria"],"enrollment":39,"completionDate":"2018-03"},{"nctId":"NCT03341741","phase":"PHASE3","title":"Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2014-03-11","conditions":["Cystic Fibrosis With Pulmonary Manifestations"],"enrollment":26,"completionDate":"2016-11-25"},{"nctId":"NCT02208154","phase":"PHASE3","title":"Ecological Effects of Decolonisation Strategies in Intensive Care","status":"COMPLETED","sponsor":"MJM Bonten","startDate":"2013-12-01","conditions":["ICU-ecology (Multidrug Resistant Bacteria)","ICU-acquired Bacteraemia"],"enrollment":8665,"completionDate":"2017-10-27"},{"nctId":"NCT01449838","phase":"PHASE1","title":"Phase I Study of Colistin Methanesulfonate Sodium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-23","conditions":["Infections, Pseudomonas"],"enrollment":22,"completionDate":"2010-12-09"},{"nctId":"NCT01931592","phase":"PHASE2,PHASE3","title":"Controling Intestinal Colonization With Extended Spectrum ß-Lactamase Producing Enterobacteriaceae ESBL-E","status":"TERMINATED","sponsor":"Maria J.G.T. Vehreschild","startDate":"2014-01","conditions":["Cancer"],"enrollment":29,"completionDate":"2016-12"},{"nctId":"NCT01266499","phase":"NA","title":"A Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2009-07","conditions":["Klebsiella Pneumoniae Carbapenemase Resistant Associated Bacteremia or Pneumonia"],"enrollment":200,"completionDate":"2012-01"},{"nctId":"NCT01845246","phase":"NA","title":"Multicentric Study About the Usefulness of Monitoring Plasma Levels of Colistin and Sodium Colistimethate in Patients With Infections Due to Multi-drug Resistant Gram Negative Bacilli, Treated With Colistin","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2012-01","conditions":["Multidrug Resistant Gram Negative Bacterial Infections"],"enrollment":101,"completionDate":"2015-08"},{"nctId":"NCT01732250","phase":"PHASE4","title":"Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem","status":"COMPLETED","sponsor":"Mical Paul","startDate":"2013-03","conditions":["Gram-Negative Bacterial Infections"],"enrollment":406,"completionDate":"2017-02-28"},{"nctId":"NCT03045692","phase":"NA","title":"Assessment of Kidney Function for Drug Dosage Adjustments in Critically Ill Patients","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2017-02-13","conditions":["ICU Patients"],"enrollment":172,"completionDate":"2019-04-30"},{"nctId":"NCT02156323","phase":"PHASE1","title":"A Phase 1 Clinical Study in Healthy Volunteers to Investigate the Drug-drug Interaction Between Multiple Doses of RO7033877 and Multiple Doses of Colistin Methanesulfonate Sodium (CMS)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-07","conditions":["Healthy Volunteer"],"enrollment":28,"completionDate":"2015-03"},{"nctId":"NCT01060891","phase":"PHASE1","title":"Population Pharmacokinetic Study of Colistin in Patients Infected With Multiresistant Gram-negative Bacteria","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2009-05","conditions":["Gram-negative Bacteria"],"enrollment":200,"completionDate":""},{"nctId":"NCT01537614","phase":"PHASE1","title":"Pharmacokinetic Study of Aerosolized Colimycin in Cystic Fibrosis","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2011-10","conditions":["Cystic Fibrosis"],"enrollment":7,"completionDate":""},{"nctId":"NCT02556190","phase":"","title":"Colistin Pharmacokinetics in Critically Ill Patients During Extended Dialysis","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2013-06","conditions":["Infection Due to Resistant Bacteria","Acute Kidney Injury"],"enrollment":8,"completionDate":"2016-05"},{"nctId":"NCT01894347","phase":"","title":"Prospective Observational Pilot-study for the Evaluation of the Nephro- an Neurotoxicity in the Anti-infectious Therapy With Inhalative Colistin Therapy for Patients With Ventilator-associated Pneumonia (VAP)","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2013-09","conditions":["Infection Resistant to Multiple Drugs"],"enrollment":9,"completionDate":"2015-12"},{"nctId":"NCT01631968","phase":"NA","title":"Incidence of Infection After Total Knee Arthroplasty Using an Erythromycin and Colistin Loaded Cement or a Standard Cement","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2007-09","conditions":["Infection After Primary Total Knee Arthroplasty"],"enrollment":2948,"completionDate":"2012-05"},{"nctId":"NCT02683603","phase":"PHASE4","title":"Effect of Aerosolised Colistin in Ventilator Associated Pneumonia","status":"COMPLETED","sponsor":"Tunis University","startDate":"2013-04","conditions":["Pneumonia, Ventilator-Associated"],"enrollment":133,"completionDate":"2015-04"},{"nctId":"NCT02408185","phase":"PHASE1","title":"Optimization Dose Study on Pharmacokinetics and Pharmacodynamics of Colistin in Critically Ill Patients","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2011-10","conditions":["Critical Illness"],"enrollment":20,"completionDate":"2013-10"},{"nctId":"NCT01292031","phase":"PHASE3","title":"Trial of Colistin Versus Meropenem in Ventilator-associated Pneumonia (VAP) (CR-GNB)","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2012-05","conditions":["Ventilator-associated Bacterial Pneumonia"],"enrollment":232,"completionDate":"2015-12"},{"nctId":"NCT00235690","phase":"NA","title":"Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2008-06","conditions":["Bacteremia","Pseudomonas Infections"],"enrollment":10,"completionDate":"2015-08"},{"nctId":"NCT02619786","phase":"PHASE3","title":"Therapy of Ventilator-associated Tracheobronchitis Caused by Gram Negative Bacteria With Nebulized Colistin","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2015-12","conditions":["Bronchitis"],"enrollment":62,"completionDate":"2017-12"},{"nctId":"NCT02604849","phase":"","title":"Efficacy of Intestinal Decontamination in Patients Colonized by Carbapenem-resistant Klebsiella Pneumoniae and Colistin","status":"COMPLETED","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2012-07","conditions":["Patients Colonized by Klebsiella Pneumoniae."],"enrollment":44,"completionDate":"2015-11"},{"nctId":"NCT02573064","phase":"","title":"Impact of Treatment With Colistin on Mortality Bacteremia Multiresistant Acinetobacter Baumannii Sensitive Colistin in Patients Critical","status":"COMPLETED","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2010-01","conditions":["Acinetobacter Infections"],"enrollment":113,"completionDate":""},{"nctId":"NCT02162966","phase":"PHASE4","title":"Safety and Efficacy Study of High Dose Colistin","status":"UNKNOWN","sponsor":"King Saud Medical City","startDate":"2014-05","conditions":["Infectious Diseases"],"enrollment":330,"completionDate":"2016-10"},{"nctId":"NCT00411736","phase":"PHASE4","title":"Scandinavian Cystic Fibrosis Azithromycin Study","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2008-05","conditions":["Cystic Fibrosis"],"enrollment":45,"completionDate":"2014-03"},{"nctId":"NCT02081560","phase":"PHASE4","title":"Colistin Pharmacokinetics in Continuous Renal Replacement Therapy","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2013-11","conditions":["Infection"],"enrollment":10,"completionDate":"2015-08"},{"nctId":"NCT01025921","phase":"NA","title":"Tracheobronchitis Prevention Trial","status":"COMPLETED","sponsor":"University of Thessaly","startDate":"2009-11","conditions":["Tracheobronchitis","Pneumonia"],"enrollment":84,"completionDate":"2013-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Auricular (Otic)","formulation":"Suspension","formulations":[{"form":"SUSPENSION","route":"AURICULAR (OTIC)","productName":"Cortisporin TC"},{"form":"SUSPENSION","route":"AURICULAR (OTIC)","productName":"Cortisporin-TC"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147787","MMSL":"11126","NDDF":"002804","UNII":"Z67X93HJG1","VUID":"4019695","CHEBI":"CHEBI:37943","VANDF":"4018640","INN_ID":"916","RXNORM":"2709","UMLSCUI":"C0009316","chemblId":"CHEMBL6067481","ChEMBL_ID":"CHEMBL2221249","KEGG_DRUG":"D02138","DRUGBANK_ID":"DB00803","PUBCHEM_CID":"44144393","SNOMEDCT_US":"23375008","IUPHAR_LIGAND_ID":"10794","SECONDARY_CAS_RN":"1264-72-8","MESH_DESCRIPTOR_UI":"D003091"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1962-","companyName":"Par Sterile Products","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"0%"},"publicationCount":12125,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"A07AA10","allCodes":["A07AA10","J01XB01"]},"biosimilarFilings":[],"originalDeveloper":"Par Sterile Products","recentPublications":[{"date":"2026 Feb 27","pmid":"41901706","title":"Fluoroquinolone-Resistant Avian Pathogenic Escherichia coli Isolated from Asymptomatic Broiler Chickens in a Slaughterhouse in Northern Thailand.","journal":"Pathogens (Basel, Switzerland)"},{"date":"2026 Mar 18","pmid":"41900447","title":"First Report and Comprehensive Risk Index of bla(IMP-1)-Harboring Brucella anthropi in Municipal Wastewater-Irrigated Soil.","journal":"Microorganisms"},{"date":"2026","pmid":"41894365","title":"A natural probioenzyme strategy as an effective alternative to antibiotics against multidrug-resistant Klebsiella pneumoniae in broilers: Benefits for growth, immunity, and organ health.","journal":"PloS one"},{"date":"2026 Mar 20","pmid":"41892479","title":"Molecular Characterization of Colistin-Resistant Clinical Acinetobacter baumannii from Northern Greece: Phenotypic Colistin Susceptibility and lpx/pmrCAB Mutational Profiles.","journal":"Antibiotics (Basel, Switzerland)"},{"date":"2026 Mar 12","pmid":"41892449","title":"Analysis of Antibiotic Consumption Trends and Pathogens' Epidemiological Profile Within a Multidisciplinary Clinical Hospital from Romania.","journal":"Antibiotics (Basel, Switzerland)"}],"combinationProducts":[{"brandName":"Cortisporin TC","ingredients":"colistin + hydrocortisone acetate + neomycin + tonzonium"},{"brandName":"Cortisporin-TC","ingredients":"colistin + hydrocortisone acetate + neomycin + tonzonium"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Par Sterile Products","companyId":"par-sterile-products","modality":"Small Molecule","firstApprovalDate":"1962","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1962-05-17T00:00:00.000Z","mah":"PAR STERILE PRODUCTS","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1964-04-16T00:00:00.000Z","mah":"PH HEALTH","brand_name_local":null,"application_number":"NDA050356"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:54:58.437578+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}